- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05045131
PeAF-BOX: Feasibility, Safety and Efficacy of PVI + Box Ablation in Persistent Atrial Fibrillation (PeAF-BOX)
PeAF-Box. A Study to Investigate the Feasibility, Safety and Efficacy of Isolating the Left Atrial Posterior Wall Adjunctive to Pulmonary Vein Isolation as First-line Therapeutical Strategy in Treatment of Persistent Atrial Fibrillation
Title: PeAF-Box. Feasibility, Safety and Efficacy of Isolating the Left Atrial Posterior Wall (PWI) added to Pulmonary Vein Isolation (PVI) as First-Line Strategy in Treatment of Persistent Atrial Fibrillation (PeAF)
Design: A prospective, observational, single center, unblinded, clinical study with 3 years of follow-up and two interventional procedures: An index ablation procedure and a reassessment/ reablation procedure after 6 months.
Background: In patients with PeAF the effect of first-line ablation with pulmonary vein isolation (PVI) is smaller than in patients with paroxysmal atrial fibrillation (PAF), where PVI alone is effective in reducing symptoms and increasing quality of life. Adding PWI to PVI is increasingly used despite concerns about safety and efficacy.
Objectives: (1) To use PVI + PWI as first-line ablation-strategy in participants with PeAF and to assess the feasibility of obtaining that goal. (2) To assess the safety of applying this lesion set - in terms of heat-induced injury to the esophagus - using esophagoscopy. 3) To asses arrhythmia burden using continuous monitoring for 3 years after ablation. (4) To assess the durability of the PVI + PWI lesion set by a relook/ reablation procedure after 6 months. (5) To follow the effect of PVI + PWI on participants' quality of life over three years.
Study site: Dept of Cardiology - Electrophysiology Laboratory, Gentofte Hospital, University of Copenhagen.
Study population: 24 patients referred for ablation of PeAF are asked for informed consent for these elements that surpass standard treatment in PeAF: (1) Taking amiodarone for 3 weeks prior to the index procedure to 3 weeks after the procedure, (2) Additional ablation with PWI compared to standard first-line therapy with PVI only. (3) Implantation of an implantable cardiac monitor (ICM), (4) Post-procedure esophagoscopy, (5) Regular clinic visits for 3 years post procedure, (6) Undergoing an interventional relook/ reablation procedure 6 months after the index procedure.
Anticoagulation drugs during the procedure and follow up: To prevent thromboses participants are prescribed periprocedural oral anticoagulant treatment to be continued for shorter or longer/lifelong periods according to the participants' risk of thrombosis (the CHA2DS2-VASC score).
Anti-arrhythmic drugs (AADs): Except from periprocedural amiodarone treatment, no AADs are allowed during the follow-up apart from occurrence of otherwise untreatable arrhythmias.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with symptomatic persistent atrial fibrillation (EHRA symptom class II or above)
- Prior failed treatment with at last one antiarrhythmic drug (Class I-IV)
- Clinical indication for ablation
Persistent atrial fibrillation meeting both the following requirements:
- One or more episodes of atrial fibrillation lasting longer than seven days, regardless of mode of termination
- Estimated cumulated time in PeAF more than 3 months and less than 36 months
Exclusion Criteria:
- Contraindication for ablation
- Predominantly PAF phenotype
- Valvular Heart disease
- Previous ablation in heart
- Previous heart surgery (including valve surgery and coronary artery bypass grafting - CABG)
- Documented atrial flutter or other arrhythmia requiring ablation besides PVI
- Greatly enlarged left atrium on Trans thoracic Echocardiography (TTE ; diameter > 52 mm in males and diameter > 47 mm in females)
- LVEF < 35%
- Implanted pacemaker or defibrillator
- Presence of intramural thombus, tumor or other abnormality precluding catheter introduction
- Pregnancy
- Intolerance to Amiodarone
- Unstable angina pectoris
- Myocardial infarction within 3 months of inclusion
- History of blood clotting or bleeding anomalies
- Malignant disease (non metastatic skin cancer excluded)
- Severe obesity (Mody mass index > 35 kg/m^2)
- Active systemic infection
- Renal insufficiency (serum creatinine > 150 mmoles/liter)
- Psychiatric illness
- Substance abuse
- Participation in other clinical trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PVI+PWI, 6 months reassessment procedure, 3 year continued rhythm monitoring
Single arm experimental, observational study: All participants receive a single-procedure combined PVI + posterior wall isolation (PVI+PWI), loop recorder implantation, esophagoscopy, a mandated interventional reassessment /reablation procedure at six months and continuous rhythm monitoring for three years
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The safety of single procedure PVI + PWI
Time Frame: Esophagoscopy is carried out at least 20 hours and less than 48 hours after the index ablation procedure
|
Defined as the incidence of inflammation or other injury to the esophagus detected under mandated esophagoscopy on the day after PVI + PWI with radiofrequency ablation.
The endoscopy is carried out, assessed and electronically stored by a board-certified gastroenterologist.
Metric: n/N in %.
|
Esophagoscopy is carried out at least 20 hours and less than 48 hours after the index ablation procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of a first-procedure PVI + PWI strategy
Time Frame: The data are available immediately after the end of the index PVI + PWI procedure
|
Defined as the ability to achieve complete bidirectional isolation of the left atrial posterior wall as well as all pulmonary veins at a reasonable cost in terms of procedure-, ablation and fluoroscopy times and total patient radiation exposure.
Electrical isolation is assessed by visual inspection of electrocardiograms and classical electrophysiological pacing- and sensing maneuvers in the left atrium.
|
The data are available immediately after the end of the index PVI + PWI procedure
|
Temperature in the esophagus during radiofrequency ablation
Time Frame: The data are available immediately after the end of the index PVI + PWI procedure
|
Defined as the maximum temperature measured in degrees Celsius with one decimal and evaluated for each individual ablation during point-by-point ablations to achieve PVI + PWI.
Metric: Degrees Celsius.
|
The data are available immediately after the end of the index PVI + PWI procedure
|
Durability of the PVI + PWI lesion set
Time Frame: The data are available immediately after the end of the six months reassessment procedure
|
Defined as the proportions of pulmonary veins and left atrial posterior walls remaining durably isolated when controlled at the six months reassessment procedure.
Electrical isolation is assessed by visual inspection of electrocardiograms and classical electrophysiological pacing- and sensing maneuvers in the left atrium.
Metric: n/N in %.
|
The data are available immediately after the end of the six months reassessment procedure
|
AF recurrence short term
Time Frame: The data are available 180 days after the index procedure
|
Defined as the proportion of participants with recurring atrial fibrillation of at least 2 minutes duration and the time to the first recurrence detected during continuous rhythm monitoring by the implanted loop recorder in the time frame of 90 days from end blanking period to 180 days post index procedure (time of scheduled reassessment procedure).
Metric: n/N in %.
|
The data are available 180 days after the index procedure
|
AF burden short term
Time Frame: The data are available 180 days after the index procedure
|
Defined as cumulated time in atrial fibrillation (minutes) divided by the total number of minutes in the 90 days observation period between end blanking period and time of scheduled reassessment procedure.
Metric: min/min in %.
|
The data are available 180 days after the index procedure
|
AF recurrence long term
Time Frame: The data are available 1080 days after the index procedure
|
Defined as the proportion of participants with recurring atrial fibrillation of at least 2 minutes duration and the time to the first recurrence detected during continuous rhythm monitoring by the implanted loop recorder in the time frame between the reassessment / reablation procedure at 180 days and full three years (1080 days) observation time after the index procedure.
Metric n/N in %.
|
The data are available 1080 days after the index procedure
|
AF burden long term
Time Frame: The data are available 1080 days after the index procedure
|
Defined as cumulated time in atrial fibrillation (minutes) divided by the total number of minutes in the 900 days observation period between the 6 months reassessment/ reablation procedure and full three years observation time (1080 days).
Moreover, AF burden is calculated every 3 to 6 months during the entire follow - up period.
Metric: min./min.
in %
|
The data are available 1080 days after the index procedure
|
Long term efficacy PVI + PWI
Time Frame: The data are available 1080 days after the index procedure
|
Defined as incidence of anti arrhythmic drug therapy and repeat ablations between the the reassessment procedure at 180 days and end follow-up at 1080 days.
Metric: number of patients and specification of drug
|
The data are available 1080 days after the index procedure
|
Effect on quality of life by PVI + PWI
Time Frame: Data are available from recruitment to end of follow-up at 3 years
|
Defined as self reported scores obtained by repeat answering of the Atrial Fibrillation Effect on Quality of Life (AFEQT) score system.
The questionnaire is administered every three to six months to coincide with clinic visits and calculation of AF burden.
Metric: range [0-100]
|
Data are available from recruitment to end of follow-up at 3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to PVI
Time Frame: Data available immediately after index procedure
|
Time from index procedure start until all (or all isolatable) pulmonary veins are electrically isolated at index procedure.
Metric: Min.
|
Data available immediately after index procedure
|
Time to PVI + PWI
Time Frame: Data available immediately after index procedure
|
Time from index procedure start until all (or all isolatable) pulmonary veins and posterior walls are electrically isolated at index procedure.
Metric: Min.
|
Data available immediately after index procedure
|
Total procedure time
Time Frame: Data available immediately after index procedure
|
Time from index procedure start until all catheters are removed from the veins.
Metric: Min.
|
Data available immediately after index procedure
|
Ablation time PVI
Time Frame: Data available immediately after index procedure
|
Cumulated time of radiofrequency (RF) energy delivery required to achieve PVI during index procedure.
Metric: min.
|
Data available immediately after index procedure
|
Ablation time PVI + PWI
Time Frame: Data available immediately after index procedure
|
Cumulated time of RF delivery required to achieve PVI + PWI during index procedure.
Metric: min.
|
Data available immediately after index procedure
|
Fluoroscopy time PVI
Time Frame: Data available immediately after index procedure
|
Cumulated X-ray delivery time from start procedure until PVI achieved during index procedure.
Metric: min.
|
Data available immediately after index procedure
|
Fluoroscopy time PVI + PWI
Time Frame: Data available immediately after index procedure
|
Cumulated X-ray delivery time from start procedure until all catheters removed from the veins in index procedure.
Metric: min.
|
Data available immediately after index procedure
|
Fluoroscopy dose PVI
Time Frame: Data available immediately after index procedure
|
Cumulated X-ray dose to the participant from start procedure until PVI achieved during index procedure.
Metric: Gy x cm^2
|
Data available immediately after index procedure
|
Fluoroscopy dose PVI + PWI
Time Frame: Data available immediately after index procedure
|
Cumulated X-ray dose to the participant from start procedure until all catheters removed from the veins in index procedure.
Metric: Gy x cm^2
|
Data available immediately after index procedure
|
Index procedure vascular access complications
Time Frame: Data available one month after completion of the index procedure
|
The number of participants developing a complication related to vascular access in the right groin.
Metric: n/N in %
|
Data available one month after completion of the index procedure
|
Index procedure tamponade/ effusions
Time Frame: Data available one day after completion of the index procedure
|
The number of participants developing symptoms and signs of pericardial effusion during or after the procedure.
Metric: n/N in %
|
Data available one day after completion of the index procedure
|
Left atrial volume
Time Frame: Data available after completion of the reassessment procedure
|
The left atrial volume before the index procedure and before the reassessment procedure after 6 months.
Estimated with 1) Contrast-CT scan of left atrium, 2) Echo - measured left atrial volume and 3) Left atrial volume estimated by electroanatomical mapping (Carto ®, Biosense Webster.Inc).
Metric: ml.
|
Data available after completion of the reassessment procedure
|
Left Ventricular Ejection Fraction (LVEF)
Time Frame: Data available 1 year after the index procedure
|
The left ventricular systolic function estimated by LVEF before the index procedure, before the reassessment procedure after 6 months and at 1 year follow-up.
Metric: %
|
Data available 1 year after the index procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: René H Worck, MD, Herlev-Gentofte Hospital, UCPH
Publications and helpful links
General Publications
- Worck R, Sorensen SK, Johannessen A, Ruwald MH, Hansen ML, Haugdal M, Hansen J. Posterior wall isolation in persistent atrial fibrillation. Long-term outcomes of a repeat procedure strategy. J Interv Card Electrophysiol. 2022 Nov 3. doi: 10.1007/s10840-022-01402-x. Online ahead of print.
- Worck R, Sorensen SK, Johannessen A, Ruwald M, Haugdal M, Hansen J. Posterior wall isolation in persistent atrial fibrillation feasibility, safety, durability, and efficacy. J Cardiovasc Electrophysiol. 2022 Aug;33(8):1667-1674. doi: 10.1111/jce.15556. Epub 2022 May 31.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PeAF-BOX study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Abbott Medical DevicesRecruitingAtrial Fibrillation | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited States, Australia, Belgium, Germany, Spain, Netherlands, France, Austria, Canada, Czechia, Italy, United Kingdom
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
Clinical Trials on Left atrial combined pulmonary vein isolation and posterior wall isolation
-
Brigham and Women's HospitalBoston Scientific CorporationNot yet recruitingAtrial Fibrillation ParoxysmalUnited States
-
Liverpool Heart and Chest Hospital NHS Foundation...Boston Scientific CorporationRecruitingAtrial Fibrillation | Persistent Atrial FibrillationUnited Kingdom
-
Texas Cardiac Arrhythmia Research FoundationCatholic University of the Sacred Heart; Capital Medical University; Centro Cardiologico...Completed
-
Insel Gruppe AG, University Hospital BernRecruiting
-
Institute for Clinical Effectiveness, JapanRecruitingPersistent Atrial Fibrillation | Catheter Ablation | Pulmonary Vein Isolation | Posterior Wall IsolationJapan
-
AtriCure, Inc.Active, not recruitingAtrial FibrillationUnited States
-
University Hospital Plymouth NHS TrustCompletedPersistent Atrial Fibrillation | Atrial Fibrillation AblationUnited Kingdom
-
McGill University Health Centre/Research Institute...Montreal Heart InstituteRecruitingAtrial FibrillationBelgium, Canada, France, Japan, Australia, Austria, United States, Italy
-
Fujian Medical UniversityCompletedCardiovascular DiseaseChina
-
Shanghai Chest HospitalCompletedPersistent Atrial Fibrillation | Right Atrial EnlargementChina